Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.

Now that his adult sons manage their own hemophilia care, columnist Joe MacDonald wonders how he can best support them.

The hemophilia market is expected to experience significant growth due to advancements in gene therapy, innovative treatments, and an increasing focus on personalized medicine. Rising awareness and ...

Columnist Alliah Czarielle doesn't want a person with an invisible disability to be perceived by businesses as a fraud.

Hemgenix is the first gene therapy for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, have current or historical life-threatening bleeding, or have ...

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated ...

provides comprehensive care for children and adolescents with hemophilia and other bleeding disorders. Our division is actively involved in the education of medical students, residents and fellows. We ...

to patients with hemophilia A or B with inhibitors, patients with autoimmune antibodies to factor VIII, and patients with bleeding associated with liver disease. These guidelines were developed by ...

Children with hemophilia often didn't make it to adulthood, since a bump or fall could cause massive internal bleeding. But why was hemophilia known as the royal disease? In the 19th century ...

When most people think about bleeding, they imagine visible wounds and blood-stained bandages. However, internal bleeding poses a far more dangerous threat precisely because it often goes ...

An expert has issued a warning about a "subtle" symptom of cancer that could suggest "internal bleeding". This easily overlooked sign might point to one of the UK's deadliest cancers. According to ...